摘要
目的探讨免疫治疗在晚期食管癌应用中的临床疗效及安全性。方法回顾性分析2019年6月至2021年10月在首都医科大学附属北京友谊医院接受免疫治疗或免疫治疗联合化疗治疗的晚期转移性食管癌患者119例。单纯免疫治疗(卡瑞利珠单抗)48例,免疫治疗联合化疗(卡瑞利珠单抗与其他化疗药物)患者71例。总结患者的临床资料,分析其客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS)和不良反应等情况。结果所有患者的中位随访时间为16.8个月。完全缓解14例(11.8%),部分缓解28例(23.5%),稳定37例(31.1%),进展40例(33.6%),ORR为35.3%,DCR为66.4%,PFS为8.4个月,OS为15.6个月。进一步分层研究中一线免疫治疗(国产卡瑞利珠单抗)联合化疗的PFS及OS进一步提高为10.3个月及19.6个月。治疗相关不良反应绝大多数为1-2级,可耐受,安全性良好。结论本研究初步证实了卡瑞利珠单抗联合化疗治疗的晚期食管癌患者生存时间延长,安全性良好。
Objective The current study is aimed to investigate the safety and clinical efficacy of immunotherapy in the treatment of advanced esophageal cancer.Methods The clinical data of 119 metastatic advanced esophageal cancer patients who received immunotherapy or immunotherapy combined with chemotherapy in Beijing Friendship Hospital from June 2019 to October 2021 were retrospectively analyzed.48 patients received immunotherapy alone(Camrelizumab),and 71 patients received immunotherapy combined with chemotherapy(Camrelizumab and other chemotherapy drugs).The objective response rate(ORR),disease control rate(DCR),progression free survival(PFS),overall survival(OS)and adverse reactions were analyzed.Results The median follow-up time was 16.8 months.Complete remission in 14 cases(11.8%),partial remission in 28 cases(23.5%),stable in 37 cases(31.1%),progression in 40 cases(33.6%),ORR was 35.3%,DCR was 66.4%,PFS was 8.4 months,OS was 15.6 months.PFS was 8.4 months and OS was 15.6 months among all patients.In this study,immunotherapy(Camrelizumab)combined with chemotherapy increased PFS to 10.3 months and OS to 19.6 months.Most of the treatment-related adverse reactions were grade 1-2,which are usually tolerable and safe to the patient.Conclusion It is confirmed,in this study,that the immunotherapy(Karelizumab)combined with chemotherapy can safely prolong the survival time of advanced esophageal cancer patients.
作者
马颖杰
胡杰轩
赵磊
林海珊
王婧
李琴
苏强
曹邦伟
MA Ying-jie;HU Jie-xuan;ZHAO Lei(Cancer Center,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)
出处
《临床和实验医学杂志》
2022年第9期955-959,共5页
Journal of Clinical and Experimental Medicine
基金
北京市自然科学基金项目(编号:KZ202010025047)
国家自然科学基金重大研究计划培育项目(编号:92046015)。
关键词
食管癌
免疫治疗
预后
不良反应
Esophageal cancer
Immunotherapy
Prognosis
Adverse effects
